Tevogen Bio secures agreement with CD8 for cell therapy production facility, enhancing research capabilities and operational efficiency.
Quiver AI Summary
Tevogen Bio announced an agreement with CD 8 Technology Services to develop a turn-key facility aimed at enhancing its in-house capabilities for pre-clinical research and GMP cell therapy production. This facility is a crucial part of Tevogen's strategy to expedite development processes, maintain flexibility, and manage costs effectively. The initial term of the agreement is 12 months and will auto-renew, aligning with earlier forecasts. Tevogen's CEO, Ryan Saadi, emphasized this milestone as a significant advancement in supporting the company's pipeline of off-the-shelf, genetically unmodified CD8+ T cell therapeutics. The agreement also addresses potential capital barriers associated with building large-scale GMP capabilities. Further details regarding the facility will be outlined in future work orders.
Potential Positives
- The agreement with CD8 Technology Services LLC facilitates the development of in-house cell therapy production capabilities, which is crucial for operational agility and cost control.
- This milestone aligns with previously announced topline forecasts, indicating a strategic fit with the company’s growth plans.
- The ability to overcome capital barriers associated with building GMP capabilities at scale may enhance Tevogen's competitive position in the biopharmaceutical industry.
- The expansion of infrastructure supports the advancement of Tevogen's pipeline of CD8+ T cell therapeutics, potentially accelerating the development timelines for these products.
Potential Negatives
- The company's reliance on an agreement with CD8 Technology Services may indicate vulnerabilities in its internal resources and capabilities for in-house production.
- The link between CD8 and a significant shareholder raises potential conflicts of interest, which could affect governance and investor confidence.
- The need for additional capital to execute its business plan is a crucial risk, as it may not be secured on favorable terms, potentially impacting future operations and growth.
FAQ
What agreement did Tevogen Bio announce?
Tevogen Bio announced an agreement with CD8 Technology Services for developing a turn-key facility for in-house research and GMP cell therapy production.
How will the new facility support Tevogen Bio?
The facility will support pre-clinical research and GMP production, allowing Tevogen Bio to accelerate development and control costs.
Who will operate the new cell therapy production facility?
Tevogen Bio will provide the primary staff and operations for the facility as part of their long-term strategy.
What is the term of the agreement with CD8?
The agreement has an initial term of 12 months and will automatically renew, aligning with previously announced forecasts.
What future opportunities does this agreement represent for Tevogen Bio?
This agreement allows Tevogen Bio to overcome capital barriers and advance its pipeline of off-the-shelf CD8+ T cell therapeutics.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$TVGN Insider Trading Activity
$TVGN insiders have traded $TVGN stock on the open market 8 times in the past 6 months. Of those trades, 0 have been purchases and 8 have been sales.
Here’s a breakdown of recent trading of $TVGN stock by insiders over the last 6 months:
- NEAL FLOMENBERG (See Remarks) has made 0 purchases and 8 sales selling 1,737,294 shares for an estimated $2,483,007.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$TVGN Hedge Fund Activity
We have seen 28 institutional investors add shares of $TVGN stock to their portfolio, and 13 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PORTLAND GLOBAL ADVISORS LLC removed 1,854,517 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $1,910,152
- POLAR ASSET MANAGEMENT PARTNERS INC. removed 1,577,387 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $1,624,708
- CANTOR FITZGERALD, L. P. removed 603,691 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $621,801
- BLACKROCK, INC. added 370,936 shares (+160.6%) to their portfolio in Q4 2024, for an estimated $382,064
- HGC INVESTMENT MANAGEMENT INC. removed 223,077 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $229,769
- UBS GROUP AG added 174,031 shares (+1644.9%) to their portfolio in Q4 2024, for an estimated $179,251
- NEW YORK STATE COMMON RETIREMENT FUND removed 119,500 shares (-94.5%) from their portfolio in Q4 2024, for an estimated $123,085
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
The agreement would facilitate providing Tevogen Bio with in-house cell therapy production capabilities
Formalized agreement aligns with previously announced topline forecasts
WARREN, N.J., April 17, 2025 (GLOBE NEWSWIRE) --
Tevogen Bio
(“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq:
TVGN
), today announced it has entered into an agreement with CD 8 Technology Services LLC (“CD8”) for the development and/or acquisition of a turn-key facility that is intended to support both in-house pre-clinical research and GMP cell therapy production capabilities.
Tevogen Bio will provide the primary staff and operations for the facility, which is a key component of the company’s long-term strategy to accelerate development timelines, maintain operational agility, and control cost. Tevogen Bio believes that this agreement should allow the Company to overcome significant capital barriers of entry that are typically faced in building GMP capabilities at scale. The agreement has an initial term of 12 months and will automatically renew and aligns with the previously announced topline forecasts.
“This milestone represents a significant step forward in Tevogen Bio’s infrastructure expansion to support the advancement of its pipeline of off-the-shelf, genetically unmodified CD8+ T cell therapeutics,” commented Ryan Saadi, MD, MPH, Founder and CEO of Tevogen Bio. “In addition, as we continue executing our mission to help patients, we’re also exploring additional ways to recognize our real, long-term shareholders.”
CD8 is associated with Dr. Manmohan Patel, who beneficially owns more than 5% of the Company’s common stock. The agreement formalizes a previously announced letter of intent. Specific details of the facility and related services, including scope of work, costs, and timelines, will be set out in one or more future work orders.
Forward Looking Statements
This press release contains certain forward-looking statements, including without limitation statements relating to: Tevogen’s plans for its research and manufacturing capabilities; Tevogen’s ability to build GMP capabilities at scale; the prospective benefits of the agreement with CD8; expectations regarding future product revenues; expectations regarding the healthcare and biopharmaceutical industries; and Tevogen’s development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer. Forward-looking statements can sometimes be identified by words such as “may,” “could,” “would,” “expect,” “anticipate,” “possible,” “potential,” “goal,” “opportunity,” “project,” “believe,” “future,” and similar words and expressions or their opposites. These statements are based on management’s expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company’s control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements.
Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; the failure to achieve Tevogen’s commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; risks related to the ability to develop, license or acquire new therapeutics; the risk of regulatory lawsuits or proceedings relating to Tevogen’s business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen’s limited operating history; and those factors discussed or incorporated by reference in Tevogen’s Annual Report on Form 10-K.
You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.
Contacts
Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.com
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
